The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Spironolactone Prevents Diabetic Nephropathy through an Anti-Inflammatory Mechanism in Type 2 Diabetic Rats
Abstract
Aldosterone induces myocardial fibrosis and vascular inflammation via proinflammatory and profibrotic cytokines. The effect of spironolactone on renal inflammation and renal function was investigated in type 2 diabetic rats. For define the molecular mechanism of spironolactone, the effect of spironolactone on the synthesis of monocyte chemotactic peptide-1 (MCP-1) and its upstream transcription factor, NF-kappaB, was evaluated in cultured mesangial cells and proximal tubular cells. There were no changes in blood glucose concentration or BP after spironolactone treatment. Spironolactone treatment significantly reduced urinary albumin excretion and ameliorated glomerulosclerosis. Urinary levels of MCP-1 were significantly increased concurrently with renal expression of MCP-1, macrophage migration inhibitory factor, and macrophage infiltration. Spironolactone treatment significantly inhibited urinary excretion of MCP-1 as well as renal MCP-1 and migration inhibitory factor expression and macrophage infiltration. In addition, aldosterone induced upregulation of MCP-1 expression and NF-kappaB transcriptional activity in cultured cells, and spironolactone reduced both NF-kappaB activation and MCP-1 synthesis. Furthermore, NF-kappaB inhibition abolished aldosterone-induced MCP-1 production. Overall, these findings suggest that aldosterone-induced NF-kappaB activation leads to activation of proinflammatory cytokines, ultimately leading to renal injury in this model. These data suggest that mineralocorticoid blockade may be a potential therapeutic target in diabetic nephropathy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effectiveness of Aldosterone Blockade in Patients With Diabetic Nephropathy
Sato, A., Hayashi, K., Naruse, M., & Saruta, T. (2003) · Hypertension · doi:10.1161/01.hyp.0000044937.95080.e9 · Cited by 466
Cited by
Inflammatory molecules and pathways in the pathogenesis of diabetic nephropathy
Navarro-González, J. F., Mora-Fernández, C., de Fuentes, M. M., & García-Pérez, J. (2011) · Nature Reviews Nephrology · doi:10.1038/nrneph.2011.51 · Cited by 1,072
The Role of Inflammatory Cytokines in Diabetic Nephropathy
Navarro-González, J. F., & Mora-Fernández, C. (2008) · Journal of the American Society of Nephrology · doi:10.1681/asn.2007091048 · Cited by 932
Mechanisms of Tubulointerstitial Fibrosis
Zeisberg, M., & Neilson, E. G. (2010) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010080793 · Cited by 868
Diabetic nephropathy – complications and treatment
Lim, A. (2014) · International Journal of Nephrology and Renovascular Disease · doi:10.2147/ijnrd.s40172 · Cited by 583
Inflammation in Diabetic Nephropathy
Lim, A. K. H., & Tesch, G. H. (2012) · Mediators of Inflammation · doi:10.1155/2012/146154 · Cited by 437
Metadata
- Authors
- Han, S.-Y., Kim, C.-H., Kim, H.-S., Jee, Y.-H., Song, H.-K., Lee, M.-H., Han, K.-H., Kim, H.-K., Kang, Y.-S., Han, J.-Y., Kim, Y.-S., & Cha, D.-R.
- Venue
- Journal of the American Society of Nephrology
- Published
- 2006-05
- Volume
- 17
- Issue
- 5
- Pages
- 1362-1372
- ISSN
- 1046-6673 (ISSN-L)
- OpenAlex
- W2156718697
- Cited by
- 172
- References
- 1
- FWCI
- 10.92
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Spironolactone Prevents Diabetic Nephropathy through an Anti-Inflammatory Mechanism in Type 2 Diabetic Rats. https://app.cochat.ai/papers/10.1681/asn.2005111196
- The paper
- Han, S.-Y., Kim, C.-H., Kim, H.-S., Jee, Y.-H., Song, H.-K., Lee, M.-H., Han, K.-H., Kim, H.-K., Kang, Y.-S., Han, J.-Y., Kim, Y.-S., & Cha, D.-R. (2006). Spironolactone Prevents Diabetic Nephropathy through an Anti-Inflammatory Mechanism in Type 2 Diabetic Rats. Journal of the American Society of Nephrology. https://doi.org/10.1681/asn.2005111196
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.